Rundu Pharmaceutical Gets Nod to Market Losartan Potassium

-- Zhuhai Rundu Pharmaceutical (SHE:002923) obtained approval from China's National Medical Products Administration for the marketing of losartan potassium, according to a Shenzhen bourse filing on Wednesday.

The drug is used for the treatment of primary hypertension and chronic heart failure.

The pharmaceutical company's shares rose by less than 2% at the close.

Mining & Metals3m ago

Earnings Flash (SDE.TO) Spartan Delta Corp. Increased 2026 Guidance and Increase To Credit Facility

$SDE.TO

Asia3m ago

ValueMax Raises SG$24 Million Through Digital Securities Issuance

ValueMax (SGX:T6I) raised over SG$23.9 million through the issuance of digital securities on the SDXX platform, according to a Wednesday filing with the Singapore Exchange.The issuance will be listed on the SDXX platform on May 7, the filing added.

$SGX:T6I

Mining & Metals3m ago

Earnings Flash (ADEN.TO) ADENTRA Posted Q1 Adjusted EPS US$0.38 per Share, vs. FactSet Est of $0.31

$ADEN.TO

Related Articles

Earnings Flash (SDE.TO) Spartan Delta Corp. Increased 2026 Guidance and Increase To Credit Facility

ValueMax Raises SG$24 Million Through Digital Securities Issuance

Earnings Flash (ADEN.TO) ADENTRA Posted Q1 Adjusted EPS US$0.38 per Share, vs. FactSet Est of $0.31